Esbriet Approval History
- FDA approved: Yes (First approved October 15th, 2014)
- Brand name: Esbriet
- Generic name: pirfenidone
- Dosage form: Capsules
- Company: InterMune, Inc.
- Treatment for: Idiopathic Pulmonary Fibrosis
Esbriet (pirfenidone) is a TGF-beta synthesis inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Development History and FDA Approval Process for Esbriet
|Oct 15, 2014|| FDA Approves Esbriet (pirfenidone) for Idiopathic Pulmonary Fibrosis|
|Jul 17, 2014||InterMune Receives FDA Breakthrough Therapy Designation for Pirfenidone, an Investigational Treatment for IPF|
|May 27, 2014||InterMune Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF|
|May 16, 2014||InterMune Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States|
|Feb 25, 2014||InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)|
|May 7, 2010||Coalition for Pulmonary Fibrosis Responds to News of Further Review of Pirfenidone By FDA|
|May 5, 2010||InterMune Receives FDA Complete Response Letter on Esbriet (pirfenidone) New Drug Application|
|Mar 10, 2010||FDA Advisory Committee Recommends Approval of InterMune's Esbriet (pirfenidone) for Idiopathic Pulmonary Fibrosis|
|Mar 5, 2010||InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone|
|Jan 6, 2010||FDA Grants Priority Review of Pirfenidone NDA for the Treatment of Patients With IPF|
|Nov 4, 2009||InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.